Program
zelenectide pevedotin
Also written as “Zelenectide pevedotin”, “BT8009” and “Zelenectide pevedotin (BT8009)”.
Its studies are mostly in Urinary Bladder Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms, led by BicycleTx.
Furthest: phase 2, since Sep 14, 20205 company-led studies, 5 open or runningNext primary completion: Jan 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BicycleTx | 55 open or running | phase 2since Sep 14, 2020 | Sep 14, 2020 | Jan 2027phase 2 · NCT04561362 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 14, 2020First study: phase 2 study in Urinary Bladder NeoplasmsFirst studyNCT04561362 · 329 enrolled · United States, Canada, France and more
- Jan 12, 2024Phase 2 study in Urinary Bladder NeoplasmsNCT06225596 · 375 enrolled · United States, Argentina, Australia and more
- Feb 18, 2025Phase 2 study in Breast NeoplasmsNCT06840483 · 66 enrolled · United States, Australia, Belgium and more
- Apr 16, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06933329 · 73 enrolled · France, Spain
- Jun 26, 2026Phase 2 study in Advanced Solid TumorsNCT07681674 · 16 planned
Ahead
- Jan 2027Primary completion: phase 2 study in Urinary Bladder NeoplasmsNCT04561362
- Mar 2028Primary completion: phase 2 study in Urinary Bladder NeoplasmsNCT06225596
- Jun 30, 2028Primary completion: phase 2 study in Breast NeoplasmsNCT06840483
- Aug 31, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06933329
TargetBeta
“A Bicycle toxin conjugate (BTC) composed of a zelenectide, a synthetic, bicyclic peptide targeting the cell adhesion molecule nectin-4 (PVRL4) and ”NCIt, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07681674Advanced Solid Tumors | 2 | Not yet recruiting | May 30, 2030 | 16 |
| NCT06933329Carcinoma, Non-Small-Cell Lung · France, Spain | 2 | Active, not recruiting | Aug 31, 2028 | 73 |
| NCT06840483Breast Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | Jun 30, 2028 | 66 |
| NCT06225596Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Mar 2028 | 375 |
| NCT04561362Urinary Bladder Neoplasms · United States, Canada, France and more | 2 | Active, not recruiting | Jan 2027 | 329 |
How it is read
Names in the registry
- “Zelenectide pevedotin”, 4 entries
- “BT8009”, 1 entry
- “Zelenectide pevedotin (BT8009)”, 1 entry
Conditions, from the studies’ own filings
- Urinary Bladder Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.